Vaccine will soon be developed for Covid19, who will win the race?

On January 11, a Chinese team reported the RNA genome sequence of a new coronavirus online, causing a strange new disease similar to new founding Chinese vahan. Within 48 hours, modernscientists, a Massachusetts biotechnology company, had synthesized the whole genome. Significantly, about 60 days later, the company, in collaboration with the Center for Vaccine Research at the National Institutes of Health, began a phase 1 human clinical trial of an RNA vaccine.

Since COVID-19 began its rapid spread around the world, scientists have worked at a considerable speed in trying to understand the virus—how it causes disease; How it spreads; why some people are aimless while others die; How to develop new, or retarget old, drugs; and how to create a safe and effective vaccine as soon as possible. The COVID-19 story represents the extraordinary capacity and speed of science in the twenty-first century, and the power of international cooperation. I am a member of canada’s COVID-19 vaccine working group, which is accused by the government of recommending COVID-19 vaccines that the country should buy for its population. I am optimistic that the world will have a safe and effective vaccine by the end of this year or early 2021. Still, I worry that people everywhere don’t have equal access to it.

The history of vaccination dates back to the late 1700s when Edward Jener developed the first vaccine, for a daubed, a turning point in the war between microbes and humans. A major victory from modern science, vaccines rely perfectly on the activation of the body’s own protective immunological mechanisms. Vaccines prevent disease, are cheap, it’s easy to deliver, and they have long-term effects. They are also the only drug that benefits not only from vaccinated people but also surrounding sparing transmission of pathogens within the community.

China to start use of Covid-19 Vaccine for one month

The vaccine will ideally do three things: protect individuals from being infected, prevent life-changing effects for those who covid-19, and block virus transmission to others. This vaccine does not require 100 percent effectiveness per three to be in addition to our defense against this powerful virus.

More than 100 vaccine candidates, including one by Moderna, are developing around the world, and about 36 have now entered human clinical trials. My optimism is not simply based on a numbers game. Nine vaccine candidates have now entered phase 3 human tests, the final step ahead of regulatory approval. The fact that completely different approaches to vaccine development all yield promising early results is very promising.

I also hope for the science behind these vaccines. For example, the power technology of RNA vaccines was initially developed to deliver genes to the body for rescheduling cells for behaviors such as stem cells. It’s the kind of science that’s changing all the vaccinations, not just developing covid-19 vaccines.

In the case of SARS-CoV-2, the novel Coronavirus that causes COVID-19, a protein that scientists are testing as vaccine candidates, is the result of advances in studying protein structures. The protein in the desired, spike protein is the Cobbel’s rosary, which is seen in all IMAGES of THE SARS-CoV-2. Because most proteins have complex 3D forms, the aim is to choose the right version of spike protein as vaccines so that when introduced to someone’s body, the immune system immediately detects it externally and begins to mount a powerful immune response guided to spike protein. The result is that the immune system is then pre-armed and ready to swing immediately into action if a person is then infected by the virus.

Science is paying Novaox, a Maryland-based company that works on this type of vaccine, recently reported the results of its Phase 1 experiment. The levels of the produced anti winds were stunning, about four times higher than those in people who are recovering from COVID-19 infection.

Scientists also use different strains of another virus called adenovirus as a naktur or a rocket to deliver genes that encode for the same spike proteins, and this also stimulates the immune response. Vector in the laboratory is engineered to repeat defective; It is that vector is able to deliver the spike gene to humans but once it did its job, vector could not repeat more. At least three groups are testing these vectors. An Aford University group with the participation of Austrazenica has used an addnovirus of chimpanzees and has now entered phase 3 tests in humans. The Beth Israel Dacouns Medical Center group uses Ad26 with the participation of Jansen Pharmacotica, a human adenovirus, and China-based Kanchino Biology has beset phase 3 tests with another human adnovirus called Ad5.

These examples are not just beautiful science (although they are science of beauty). By inhibiting the increased power of biological sciences, researchers are developing whole new ways to rapidly develop vaccines.

My optimism doesn’t stop with these early results, though that are key. I’m also encouraged because at least five very different approaches (I’d walk through only the top three) are being investigated to build a vaccine. As we say in Canada, if you want to win, you have to have a lot of shots to goal.

Equally important is the unprecedented global collaboration among scientists around the world, as well as the high degree of collaboration between scientists and doctors, biopharmaceutical companies, government, humanitarian funders, and regulators. They all work together towards a common goal of developing as soon as possible a safe and effective vaccine against COVID-19.

I don’t know which of the vaccine candidates undergoing clinical trials in humans will ultimately be safe and effectively shown. They may all prove effective, though in different age groups or in people with different pre-existing conditions. But the most grate news is that all vaccine candidates who have ever been tested in humans are safe and have evoked high levels of antibody against COVID-19. Some have also been shown to activate our immune system’s cellular arm, another very important element of our defense against external pathogens.

The essential public health to obtain a safe and effective vaccine as soon as possible goes hand-in-hand with the inquisition that processes higher approval of any political considerations and is based solely on data from clinical trials. Anything else risks losing people’s trust in a vaccine or, in a worst-case scenario, may lead to vaccines that are less effective than those that may be approved later, or the state-wide vaccine that turns out to be serious adverse side effects. It will be a public health tragedy.

Developing vaccines and obtaining appropriate regulatory approval are just the first two steps. The world will need billions of doses and billions of dollars in vaccines to produce and release them. My main concern throughout this process is that the government is not spending enough money to make vaccines to treat any adult on Earth. Ensuring equitable access to vaccines is crucial, not just a terrible point for rich countries. They also benefit. If the virus is anywhere, it’s everywhere. Countries must demonstrate the same desire to engage scientists from around the world and participate in the COVID-19 vaccine test, which was shown by nearly half a million people who will volunteer until it is over.

The United States, the richest country in the world and historically the first of its kind, has yet to help develop multi-forecast initiatives to buy vaccines for the developing world, at its own request and under its own leadership. To date, 75 industrial countries have agreed to finance the purchase of vaccines in 90 low-income countries. But the United States is not one of them.

The cost of producing enough gasoline to vaccinate every adult on the planet could run into the hundreds of billions of dollars. But compared with the trillions of dollars the government is now charging to help those who have lost their jobs and promoted the economy, $100 billion to $200 billion is a bargain and an insurance policy that developed countries cannot afford.


If people around the world, regardless of gender, citizenship, race, color, or the ability to pay for equality and timely access to safe and effective vaccines for COVID-19, the world will emerge from this more powerful epidemiologist than it has experienced. COVID-19 epidemiologists have placed global challenges such as climate change and the development of access to sustainable energy on the back end. Once this clamping is over, we need to re-focus on the problems our planet faced before COVID-19. If we can eradicate COVID-19 through scientific and global collaboration, imagine what else we can do.